Literature DB >> 31707521

Management Strategies for Nocturia.

Danielle J Gordon1, Curran J Emeruwa2, Jeffrey P Weiss2.   

Abstract

PURPOSE OF REVIEW: Nocturia is defined as awakening due to the desire to void during a period of intended sleep. The pathophysiology of nocturia is multifactorial and management remains a challenge. Herein, we provide an overview of the management strategies for nocturia and summarize the existing evidence for treatment of nocturia across the condition's broad etiologic categories: nocturnal polyuria, diminished bladder capacity, and global polyuria. RECENT
FINDINGS: Treatment should begin with behavioral modification. A high level of evidence supports the efficacy of desmopressin in the treatment of nocturnal polyuria. Data supporting the efficacy of α-blockers, antimuscarinics, and surgical bladder outlet procedures in the treatment of nocturia remains limited. Treatment options for nocturia are determined by underlying mechanism. Desmopressin is effective in treating nocturnal polyuria. Surgical intervention, α-blockers, and antimuscarinics may improve nocturia when associated with lower urinary tract symptoms or overactive bladder in the setting of diminished bladder capacity.

Entities:  

Keywords:  Diminished bladder capacity; Global polyuria; Nocturia; Nocturia management; Nocturia treatment; Nocturnal polyuria

Year:  2019        PMID: 31707521     DOI: 10.1007/s11934-019-0940-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  45 in total

Review 1.  SSRIs and the syndrome of inappropriate antidiuretic hormone secretion.

Authors:  Carole Noelle Rottmann
Journal:  Am J Nurs       Date:  2007-01       Impact factor: 2.220

2.  Changes in detrusor innervation with relief of outflow tract obstruction.

Authors:  J A Cumming; G D Chisholm
Journal:  Br J Urol       Date:  1992-01

3.  Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial.

Authors:  Jeffrey P Weiss; Norman R Zinner; Bjarke M Klein; Jens Peter Nørgaard
Journal:  Neurourol Urodyn       Date:  2012-03-22       Impact factor: 2.696

4.  A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo.

Authors:  J M Reynard; A Cannon; Q Yang; P Abrams
Journal:  Br J Urol       Date:  1998-02

Review 5.  Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms.

Authors:  J R Swanson; G R Jones; W Krasselt; L N Denmark; F Ratti
Journal:  J Forensic Sci       Date:  1997-03       Impact factor: 1.832

Review 6.  Pygeum africanum for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Nocturia in arterial hypertension: a prevalent, underreported, and sometimes underestimated association.

Authors:  Carlos A Feldstein
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

8.  Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.

Authors:  Peter K Sand; Roger R Dmochowski; Jyotsna Reddy; Egbert A van der Meulen
Journal:  J Urol       Date:  2013-02-20       Impact factor: 7.450

9.  Predictors of nocturia quality of life before and shortly after prostatectomy.

Authors:  David Margel; David Lifshitz; Nava Brown; Dov Lask; Pinhas M Livne; Raanan Tal
Journal:  Urology       Date:  2007-09       Impact factor: 2.649

10.  Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.

Authors:  D Marples; S Christensen; E I Christensen; P D Ottosen; S Nielsen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more
  1 in total

1.  Managing Nocturia in Frail Older Adults.

Authors:  Dylan T Wolff; Kerry A Adler; Corey S Weinstein; Jeffrey P Weiss
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.